Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy
FPI-2265 positioned to be the first approved PSMA targeted alpha therapyHAMILTON, ON and BOSTON, Feb. 16, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on